Savant Capital LLC Acquires New Holdings in Phathom Pharmaceuticals, Inc. $PHAT

Savant Capital LLC bought a new position in shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 11,771 shares of the company’s stock, valued at approximately $113,000.

Several other large investors have also modified their holdings of the business. 683 Capital Management LLC raised its position in shares of Phathom Pharmaceuticals by 41.0% during the 1st quarter. 683 Capital Management LLC now owns 1,445,000 shares of the company’s stock worth $9,060,000 after purchasing an additional 420,000 shares during the last quarter. Propel Bio Management LLC raised its holdings in shares of Phathom Pharmaceuticals by 14.6% in the first quarter. Propel Bio Management LLC now owns 1,134,927 shares of the company’s stock worth $7,116,000 after acquiring an additional 145,000 shares during the last quarter. Jacobs Levy Equity Management Inc. acquired a new position in shares of Phathom Pharmaceuticals in the first quarter worth $3,738,000. Trexquant Investment LP lifted its position in shares of Phathom Pharmaceuticals by 5.3% in the first quarter. Trexquant Investment LP now owns 398,751 shares of the company’s stock valued at $2,500,000 after acquiring an additional 20,114 shares in the last quarter. Finally, Wellington Management Group LLP boosted its stake in shares of Phathom Pharmaceuticals by 47.6% during the first quarter. Wellington Management Group LLP now owns 200,690 shares of the company’s stock valued at $1,258,000 after acquiring an additional 64,695 shares during the last quarter. 99.01% of the stock is currently owned by institutional investors and hedge funds.

Phathom Pharmaceuticals Stock Performance

Phathom Pharmaceuticals stock opened at $14.36 on Friday. Phathom Pharmaceuticals, Inc. has a 1 year low of $2.21 and a 1 year high of $16.08. The firm has a 50 day moving average price of $12.84 and a 200 day moving average price of $9.94. The company has a market cap of $1.02 billion, a price-to-earnings ratio of -3.76 and a beta of 0.47.

Phathom Pharmaceuticals (NASDAQ:PHAT) last announced its quarterly earnings results on Thursday, October 30th. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.15. The company had revenue of $49.50 million during the quarter, compared to analyst estimates of $47.03 million. Phathom Pharmaceuticals has set its FY 2025 guidance at EPS. Sell-side analysts predict that Phathom Pharmaceuticals, Inc. will post -4.78 EPS for the current year.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. Guggenheim reissued a “buy” rating and issued a $20.00 target price on shares of Phathom Pharmaceuticals in a research note on Thursday, October 30th. Wall Street Zen raised shares of Phathom Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, October 18th. HC Wainwright upped their price objective on shares of Phathom Pharmaceuticals from $20.00 to $26.00 and gave the company a “buy” rating in a research note on Friday, October 31st. Craig Hallum reaffirmed a “buy” rating and issued a $22.00 target price on shares of Phathom Pharmaceuticals in a research note on Friday, October 31st. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Phathom Pharmaceuticals in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $20.67.

Phathom Pharmaceuticals Company Profile

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.